Recruiting PHASE3 Depressive Disorder, Major

Tests treatment safety and results for Depressive Disorder, Major

Official title A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

ClinicalTrials.gov ID: NCT07227454

What this study is testing

What is Esketamine?

Esketamine is an investigational medicine, being studied as a potential treatment for depressive disorder, major.

Also referred to as JNJ-54135419.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.
  • Phase 3: a large, late-stage study
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 12 to 17

You may be able to join if

  • Must meet diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD) based...
  • Must have a clinical global impression - severity of suicidality - revised (CGI-SS-R) score of "Markedly" or greater (that is, greater than or equal...
  • Must have a children's depression rating scale - revised (CDRS-R) total score \>= 58 at baseline (predose)
  • In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to subject's acute suicidality
  • Must be medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening

You likely can't join if

  • Participant has a current DSM-5 diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder...
  • Participant currently meets DSM-5 criteria for borderline personality disorder
  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychosis
  • Participant has a history of seizure disorder
  • Participant has known allergies, hypersensitivity, intolerance or contraindications to midazolam, esketamine or ketamine, or their excipients

The study team makes the final eligibility decision.

Where it's taking place

  • Birmingham, Alabama, United States
  • Atlanta, Georgia, United States
  • Evanston, Illinois, United States
  • Cincinnati, Ohio, United States
  • East Providence, Rhode Island, United States
  • Houston, Texas, United States
  • Criciúma, Brazil
  • Salvador, Brazil
  • São Bernardo do Campo, Brazil
  • São Paulo, Brazil
  • Debrecen, Hungary
  • Győr, Hungary
  • Szeged, Hungary
  • Acireale, Italy
  • Florence, Italy
  • Foggia, Italy
  • Naples, Italy
  • Sassari, Italy
  • Barcelona, Spain
  • Esplugues de Llobregat, Spain

+ 6 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 12 years to 17 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Birmingham, Alabama, United States; Atlanta, Georgia, United States; Evanston, Illinois, United States; Cincinnati, Ohio, United States; East Providence, Rhode Island, United States; Houston, Texas, United States and 20 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.